Furthermore, variations in the risk of developing BrCa have been reported in relation to molecular subtypes, defined by estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression [6,7,8]. This evidence concerns the gene PGR and invasive breast carcinoma.